Drug Discovery World

NOVEMBER 4, 2022

New research has furthered our understanding of the immune-related factors that drive infection and disease, which will be necessary for an effective tuberculosis (TB) vaccine to be developed. infection in infants who became infected with the bacteria but did not progress to active TB. Most individuals infected with M.tb

Vaccination 52

Vaccination Vaccine Development Bacteria 52

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. million deaths every year.

Vaccination 81

Vaccination Vaccine Immune Response Bacteria 81

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

Pharmaceutical Technology

DECEMBER 21, 2023

This innovative composition induces a protective immune response against Group A Streptococcus (GAS) bacteria, offering potential targets for vaccine development. Discover a groundbreaking immunogenic composition patent that combines GAS polypeptide antigens and polypeptide-polysaccharide conjugates.

Immune Response 100

Immune Response Bacteria Vaccination Vaccine 100

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

Drug Discovery World

MARCH 27, 2024

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. billion people estimated to be infected with the bacteria, according to the World Health Organization (WHO).

Vaccination 52

Vaccination Vaccine Bacteria Clinical Trials 52

Scienmag

MAY 9, 2021

Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores.

Bacteria 49

Bacteria Vaccination Vaccine Research 49

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

Scienmag

NOVEMBER 9, 2020

— Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS […].

Vaccination 98

Vaccination Vaccine Bacteria Development 98

Drug Discovery World

APRIL 25, 2024

Reece Armstrong offers an overview of cell line development and outlines the benefits the technology is bringing to biopharmaceutical developers. Cell line development is an essential underpinning of the drug development process, enabling teams to test, optimise and manufacture therapeutics at a commercial scale.

Development 59

Development Protein In-Vivo Life Science 59

XTalks

JULY 25, 2023

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). What Is Anthrax? How Does Cyfendus Work?

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccination 117

Vaccination Vaccine Bacterium Protein 117

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

Drug Discovery World

FEBRUARY 22, 2023

A research effort to develop an mRNA vaccine against Group A Streptococcus (Strep A) has secured almost $8 million in funding. The Strep A bacteria causes strep throat and scarlet fever and is a major driver of antibiotic use in children.

Vaccination 52

Vaccination Vaccine Research Bacteria 52

Medical Xpress

DECEMBER 23, 2022

If B cells are the munitions factories of the immune system, manufacturing antibodies to neutralize harmful pathogens, then the tiny biological structures known as germinal centers are its weapons-development facilities.

Bacteria 105

Bacteria Antibody Manufacturing Vaccination 105

XTalks

AUGUST 17, 2022

August is National Immunization Awareness Month (NIAM), which is marked to help raise awareness about the importance of vaccines in the protection of public health. One of the themes of this year’s National Immunization Awareness Month is “vaccines work.” Vaccination Awareness from the FDA.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

pharmaphorum

SEPTEMBER 28, 2021

Prospects for Valneva’s COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease. billion contract to supply up to 100 million doses of its COVID-19 vaccine VLA2001.

Vaccination 103

Vaccination Vaccine Bacteria Protein 103

Drug Discovery World

APRIL 26, 2024

The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery. News round-up for 22-26 April by DDW Digital Content Editor Diana Spencer.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Bacteria 52

XTalks

APRIL 28, 2021

Stories about the development of COVID-19 vaccines have dominated the news for months, but a huge breakthrough in the prevention of another infectious disease has just been announced. Read the full articles here: Malaria Vaccine a Breakthrough Success with 77 Percent Efficacy. How Sugar May Impair Brain Development in Children.

Life Science 52

Life Science Vaccination Vaccine Development 52

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . VLA15 is the only Lyme disease vaccine candidate currently in clinical development. Valneva Pfizer Report Positive Phase 2 Pediatric Data for Lyme Vaccine Candidate.

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

Drug Discovery World

JULY 28, 2023

A report by University of Queensland (UQ) researchers has warned a global crisis of antibiotic resistance is inevitable, despite promising developments in new antibiotics. Sixty-two new antibiotics in development is still very low compared to almost 2,000 in the cancer drug pipeline. million deaths were associated.

Bacteria 97

Bacteria Doctors Doctor Development 97

Pfizer

FEBRUARY 16, 2023

who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy, safety and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. OspA is a surface protein expressed by the bacteria when present in a tick.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Drug Discovery World

MARCH 17, 2023

Artificial sweetener dampened T cell response in mice Scientists at the Francis Crick Institute have found that high consumption of a common artificial sweetener, sucralose, lowers activation of T cells in mice.

Bacteria 52

Bacteria Drugs Scientist Vaccination 52

Drug Discovery World

APRIL 14, 2023

Perhaps most significantly, Ghana accepted the R21/Matrix-M malaria vaccine for use in children, Moderna revealed that cancer vaccines could be ready by 2030, and a new treatment for long Covid fatigue could be available soon. The post This week in drug discovery (10-14 April) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Bacteria Vaccination Vaccine 52

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

Drug Discovery World

APRIL 24, 2023

Danish biotech MinervaX has launched the first Phase I clinical study in older adults of its novel Group B Streptococcus (GBS) vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. There is currently no vaccine available. GBS is a global unmet medical burden and can cause serious illness in people of all ages, worldwide.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The post GSK bolsters vaccines division with $3.3bn swoop on Affinivax appeared first on. GlaxoSmithKline has agreed a $3.3

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. Valneva and Pfizer entered into a collaboration agreement in April 2020 to co-develop VLA15 2.

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

Drug Discovery World

JULY 12, 2022

Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by the World Health Organisation (WHO). . Bacteria noted in WHO’S priority pathogens list pose a significant health risk due to their resistance to antibiotics.

Vaccination 52

Vaccination Vaccine Bacteria Development 52

The Pharma Data

MARCH 8, 2021

Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. It will compare the three-dose vaccination schedule (Month 0-2-6) with a two-dose schedule (Month 0-6). “We We are excited to be part of the Lyme disease vaccine development program with Valneva.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

Delveinsight

JULY 27, 2021

Cognito Therapeutics located in Cambridge is a clinical-stage company developing novel digital therapeutics that presented clinical data on gamma frequency neuro-modulation on cognitive function from its lead digital therapeutic candidate in AD. It exhibited sleep improvement, betterments in memory and cognition, and lowered brain atrophy.

Vaccination 96

Vaccination Vaccine Trials Manufacturing 96

XTalks

FEBRUARY 11, 2021

Amidst growing global shortages of COVID-19 vaccine supplies, inaugural (by way of authorizations/approvals) COVID-19 vaccine maker Pfizer is addressing the issue by working to cut the manufacturing time of its vaccine by almost half. Related: Pharma Rivals Step Up to Assist with COVID-19 Vaccine Production.

Manufacturing 52

Manufacturing Vaccination Vaccine DNA 52

Delveinsight

SEPTEMBER 7, 2021

Pfizer’s RSV Vaccine enters in the late-stage of clinical trials. As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market heats up, Pfizer is launching a critical late-stage study of its experimental vaccine against a severe version of a cold virus that may cause pneumonia and death in the young and elderly.

Vaccination 70

Vaccination Vaccine Antibody Trials 70

pharmaphorum

JUNE 20, 2022

stake in French vaccines developer Valneva at a cost of €90.5 million (around $95 million) and rejigged the terms of their alliance to develop a shot for Lyme disease. With prospects for the COVID-19 vaccine speculative at best, VLA15 looks like Valneva’s best shot at sustainable revenues. Pfizer has acquired an 8.1%

Vaccination 91

Vaccination Vaccine Licensing Licensing 91

Drug Discovery World

MARCH 21, 2023

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. The team used two safeguard methods to prevent the bacteria and their modified genes from escaping into the wild.

Engineer 52

Engineer Genetic Engineering Scientist Bacteria 52

XTalks

OCTOBER 14, 2022

Boostrix is the first vaccine in the US indicated for the protection of newborns under two months of age from pertussis. The vaccine is a Tdap vaccine (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) that can be administered during the third trimester of pregnancy.

FDA Approval 98

FDA Approval Vaccination Vaccine Protein 98